{
  "event_id": "1f7158fe36a4",
  "ticker": "ABBV",
  "company_name": "AbbVie",
  "drug_name": "EMRELIS",
  "pdufa_date": "20250514",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:LUMINOSITY Phase 2 (Accelerated Approval 2025)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:00.706958",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Advanced NSCLC with high c-Met overexpression",
    "source": "websearch:LUMINOSITY Phase 2 (Accelerated Approval 2025)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:00.706960",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "telisotuzumab vedotin-tllv",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:05:16.351049",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Oncology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.396958",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Phase 3",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:05:16.351049",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:LUMINOSITY Phase 2 (Accelerated Approval 2025)",
    "confidence": 0.9,
    "evidence": [
      "LUMINOSITY Phase 2 (Accelerated Approval 2025)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:00.706922",
    "error": null
  },
  "p_value": {
    "status": "not_applicable",
    "value": null,
    "source": "websearch:LUMINOSITY Phase 2 (Accelerated Approval 2025)",
    "confidence": 0.9,
    "evidence": [
      "Single-arm or accelerated approval - no comparator p-value"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:00.706951",
    "error": null
  },
  "p_value_numeric": 0.0001,
  "effect_size": {
    "status": "found",
    "value": "ORR 35%; median DOR 7.2 months",
    "source": "websearch:LUMINOSITY Phase 2 (Accelerated Approval 2025)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:00.706954",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors"
  ],
  "nct_ids": [
    "NCT02099058"
  ],
  "enrollment": {
    "value": 237,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:39:05.086458",
  "enriched_at": "2026-01-11T22:03:52.261872",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "09a3feceefac",
  "fda_designations": {
    "breakthrough_therapy": false,
    "fast_track": false,
    "priority_review": true,
    "orphan_drug": false,
    "accelerated_approval": false
  },
  "mechanism_of_action": "TNF inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -241,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:36.805314",
  "is_single_arm": {
    "value": true,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "interventionModel=SEQUENTIAL",
      "allocation=NON_RANDOMIZED"
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-11T08:27:56.946457",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "trial_region": {
    "value": "global",
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "countries=['ITALY', 'BELGIUM', 'SOUTH KOREA', 'FINLAND', 'NETHERLANDS']..."
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-11T08:27:56.946495",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:31:25.885112"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:31:25.885121"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T22:03:34.565060",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T22:03:40.772158",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Telisotuzumab Vedotin-tlly (Emrelis) - clinician.com"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T22:03:44.958152",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T22:03:51.253799",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "U.S. FDA Approves EMRELISâ„¢ (telisotuzumab vedotin-tllv) for ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T22:03:52.261859",
    "search_status": "FOUND"
  }
}